Coronavirus Vaccine Development: Progress Against COVID-19
Coronavirus vaccine development has become one of the most urgent priorities in modern medicine. Researchers across the United States are accelerating efforts to find effective solutions against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Two major programs, one based in Pittsburgh and another in Boston, are leading the way with promising early results.
University of Pittsburgh: A Patch That Fights the Virus
Scientists at the University of Pittsburgh School of Medicine published groundbreaking research in EBioMedicine, a journal from The Lancet. Their approach to coronavirus vaccine development relies on a microneedle array — a fingertip-sized patch that delivers the virus’s spike protein directly through the skin. This method is designed to boost immune response more efficiently than traditional injections, and early results have been encouraging.
The spike protein is a critical target in vaccine research because it is what the virus uses to enter human cells. By training the immune system to recognize and fight it, the vaccine aims to prevent infection before it can take hold. The Pittsburgh team was able to move quickly in part because of prior experience studying related coronaviruses during the SARS outbreak in 2003 and the MERS epidemic in 2014.
“We had previous experience on SARS-CoV in 2003 and MERS-CoV in 2014,” said Dr. Andrea Gambotto, co-senior author of the study. “These closely related viruses underscore the importance of the spike protein in immunity. We knew precisely how to combat this new virus.”
Janssen and Beth Israel: A Collaborative Approach
Meanwhile, Janssen Pharmaceutical Co — a division of Johnson & Johnson — announced a partnership with Beth Israel Deaconess Medical Center (BIDMC) to advance coronavirus vaccine development through a separate line of research. Janssen initiated preclinical testing of multiple vaccine candidates in collaboration with Dr. Dan Barouch, a leading virologist at BIDMC.
The Center for Virology and Vaccine Research at BIDMC brings extensive experience to this effort, having previously worked with Janssen on vaccines for Zika and HIV. This history of collaboration allows the team to apply established methods to an entirely new challenge.
Janssen’s coronavirus vaccine development program uses two proprietary technologies: AdVac and PER.C6. These platforms have already proven effective in the development of investigational vaccines for Ebola, RSV, Zika, and HIV, providing a strong foundation for COVID-19 research.
“We are currently evaluating a series of potential vaccine candidates for COVID-19,” said Dr. Barouch. “This collaboration with Janssen is aimed at the development of a COVID-19 vaccine that would allow for rapid development, large-scale manufacturing, and global delivery.”
Janssen has also established a partnership with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services. This federal support reinforces the scale and urgency of coronavirus vaccine development efforts nationwide.
Why Clinical Trials Matter
Both programs highlight a broader truth: vaccine research requires sustained investment, infrastructure, and institutional expertise. Clinical trials are the cornerstone of this process. Before any vaccine can be approved for public use, it must go through rigorous phases of testing to confirm safety, tolerability, and efficacy across diverse populations.
FOMAT participates in infectious disease research and vaccine trials as part of its broader commitment to advancing clinical science. Our network of investigator sites supports Phase I through Phase IV studies, offering sponsors access to experienced teams and diverse patient populations across the country.
“That’s why it’s important to fund vaccine research,” Dr. Gambotto noted. “You never know where the next pandemic will come from.”
Coronavirus vaccine development will continue to evolve as new data emerges. Staying informed and supporting clinical research is one of the most important contributions the medical community and the public can make in the fight against emerging infectious diseases.
For More Information
- To read more about this news, click here
- To learn more about our active studies, click here


